MA45124B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents
Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patientsInfo
- Publication number
- MA45124B1 MA45124B1 MA45124A MA45124A MA45124B1 MA 45124 B1 MA45124 B1 MA 45124B1 MA 45124 A MA45124 A MA 45124A MA 45124 A MA45124 A MA 45124A MA 45124 B1 MA45124 B1 MA 45124B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- antibody
- biomarker
- level
- sample
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45124A MA45124A (fr) | 2017-12-07 |
| MA45124B1 true MA45124B1 (fr) | 2021-05-31 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45124A MA45124B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (enExample) |
| EP (2) | EP3916392B1 (enExample) |
| JP (2) | JP7066639B2 (enExample) |
| KR (1) | KR102416144B1 (enExample) |
| CN (2) | CN115932265A (enExample) |
| AU (1) | AU2017272608B2 (enExample) |
| BR (1) | BR112018074603A2 (enExample) |
| CY (1) | CY1124768T1 (enExample) |
| DK (2) | DK3916392T3 (enExample) |
| EA (1) | EA201892542A1 (enExample) |
| ES (2) | ES2878156T3 (enExample) |
| FI (1) | FI3916392T3 (enExample) |
| HR (2) | HRP20240670T1 (enExample) |
| HU (2) | HUE067450T2 (enExample) |
| IL (1) | IL263103B2 (enExample) |
| LT (2) | LT3465214T (enExample) |
| MA (2) | MA45124B1 (enExample) |
| MD (2) | MD3916392T2 (enExample) |
| MX (2) | MX388502B (enExample) |
| PL (2) | PL3916392T3 (enExample) |
| PT (2) | PT3465214T (enExample) |
| RS (2) | RS62155B1 (enExample) |
| SG (2) | SG10201911958SA (enExample) |
| SI (2) | SI3465214T1 (enExample) |
| SM (2) | SMT202400204T1 (enExample) |
| WO (1) | WO2017207574A1 (enExample) |
| ZA (2) | ZA201808647B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| MX2021013101A (es) * | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| IL317199A (en) * | 2019-10-31 | 2025-01-01 | Morphosys Ag | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| MX2022005032A (es) * | 2019-10-31 | 2022-07-27 | Morphosys Ag | Terapia secuencial anti cumulo de diferenciacion 19 (cd19). |
| US20220184208A1 (en) * | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009160A1 (en) * | 1998-08-11 | 2000-02-24 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| EP1389203B8 (en) | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| KR101289537B1 (ko) * | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| MX2007015944A (es) | 2005-06-20 | 2008-03-07 | Medarex Inc | Anticuerpos cd19 y sus usos. |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| ATE501436T1 (de) * | 2006-09-13 | 2011-03-15 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| JP2013543869A (ja) * | 2010-11-15 | 2013-12-09 | メディミューン，エルエルシー | Ｂ細胞リンパ腫のための併用療法 |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| AU2012296905B2 (en) * | 2011-08-16 | 2017-01-05 | Incyte Corporation | Combination therapy with an anti - CD19 antibody and a purine analog |
| SI2744515T1 (sl) * | 2011-08-16 | 2022-05-31 | Morphosys Ag | Kombinirana terapija s protitelesom proti CD19 in dušikovim iperitom |
| WO2013090478A1 (en) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Predicting responsiveness to antibody maintenance therapy |
| EP3110445A4 (en) * | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| CA2951427A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| EP3167288B1 (en) * | 2014-07-11 | 2021-10-20 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosing hematological cancers |
-
2017
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt active Search and Examination
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45124B1 (fr) | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients | |
| Varettoni et al. | Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms | |
| Lampson et al. | Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity | |
| Holmgren et al. | Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. | |
| Palm et al. | The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers | |
| Sugimori et al. | Origin and fate of blood cells deficient in glycosylphosphatidylinositol‐anchored protein among patients with bone marrow failure | |
| Fan et al. | Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation | |
| Kim et al. | CD79B and MYD88 mutations in diffuse large B-cell lymphoma | |
| Chen et al. | Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling | |
| Heidel et al. | The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML | |
| Pan et al. | A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy | |
| Galatola et al. | Gene expression profile of peripheral blood monocytes: a step towards the molecular diagnosis of celiac disease? | |
| Shinohara et al. | A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction | |
| Akhter et al. | CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series | |
| Sippert et al. | Association of duffy blood group gene polymorphisms with IL8 gene in chronic periodontitis | |
| Tambur et al. | HLA-DQ barrier: Effects on cPRA calculations | |
| Worasilchai et al. | Monitoring anti-Pythium insidiosum IgG antibodies and (1→ 3)-β-d-Glucan in vascular pythiosis | |
| US10725029B2 (en) | Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample | |
| Carbone et al. | Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy | |
| Isidro-Hernández et al. | Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice | |
| Dehmel et al. | Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome | |
| Hannula-Jouppi et al. | Genetic susceptibility to non-necrotizing erysipelas/cellulitis | |
| Sun et al. | Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration | |
| Yamauchi et al. | Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma | |
| Brown et al. | Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T |